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Abstract
Background & Aims: Metabolic syndrome (MetS) has become an important public concern due to its increasing prevalence.
An altered fatty acid composition has been associated with MetS, but the Mediterranean diet has been shown to have a
protective effect. The aim of the present study was to analyze the influence of a Mediterranean dietary pattern, as assessed
by the biomarkers of food supplied, on the plasma fatty acid composition and its relation with MetS after 1 year of
intervention.
Methods: A total of 424 subjects were randomly selected from the PREDIMED randomized dietary trial after completing a 1-
year intervention program. Participants aged 55 to 80 years and at high risk of cardiovascular disease were randomly
assigned to three dietary interventions: Mediterranean diet supplemented with virgin olive oil or nuts, or a low-fat diet.
Results: After 1 year of intervention participants in the virgin olive oil group showed significantly increased plasma
concentrations of palmitic and oleic acids, but reduced proportions of margaric, stearic, and linoleic acids. In turn, subjects
in the nut group showed significantly increased levels of palmitic, linoleic, and a-linolenic acids, but reduced proportions of
myristic, margaric, palmitoleic, and dihommo-c-linoleic acids. Increases in the biomarkers of foods supplied to the
Mediterranean diet groups, i.e., oleic and a-linolenic acids, were beneficially associated with the incidence, reversion and
prevalence of MetS. No weight changes were observed among participants.
Conclusions: The nut and olive oil diets induced a fatty acid composition that has been shown to be beneficial in the face of
MetS. Therefore, a Mediterranean diet rich in fats of vegetable origin may be a useful tool for the management of MetS
without the need for concerns over weight gain due to its high fat content.
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Introduction
Metabolic syndrome (MetS) is defined as a clustering of
interrelated metabolic risk factors that include dyslipidemia,
hypertension, elevated fasting glucose and abdominal obesity [1].
The condition is widespread among adults from developed
countries, with a prevalence of about 20 to 30%, or even higher,
and with further increases in prevalence predicted due to the
increasing incidence of obesity, diabetes and sedentary lifestyles
[2,3]. As people with MetS are at increased risk of developing both
cardiovascular disease (CVD) [4] and type 2 diabetes [5], it has
become an important public health concern and several organi-
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zations have attempted to formulate simple criteria for its diagnosis
[3].
According to current guidelines, the first step in the manage-
ment of MetS should emphasize therapeutic lifestyle modifications
[6]. Although there is general agreement about reducing weight
and increasing physical activity, a uniform consensus is lacking as
to which diet is optimal [7]. However, epidemiological evidence
suggests that individuals with MetS should adhere to a diet low in
saturated and trans fats, cholesterol, sodium, and simple sugars,
with an increased intake of fruits, vegetables, fish, and whole grains
[6,7]. Interestingly, these features resemble the principles of the
traditional Mediterranean diet (MD) [8].
During the last few decades the MD has gained in popularity
worldwide due to its reported contribution to lower rates of
morbidity (particularly CVD, certain types of cancer, and other
chronic conditions) and mortality, and the better health and
quality of life of those who adhere to it [8]. Only a few cross-
sectional, cohort and intervention studies have analyzed the
relationship between MD adherence and the prevalence or
incidence of MetS. However, the results from these studies have
provided some evidence of the beneficial role of the MD in MetS
and its components [9].
Although the dietary guidelines suggested for people presenting
with MetS are similar to those of the MD and other healthy
dietary patterns, the MD has a peculiarity of its own: a high
content of total fat. This is the most distinguishing feature of the
MD, with virgin olive oil (VOO) being the primary source of fat
(providing 70–80% of the total fat). Unlike other oils however, the
health-giving properties of VOO are derived not solely from its
MUFA content (70–80% due to oleic acid), but also from minor
components with great biological activity, including squalene,
sterols, tocopherol, and highly bioavailable phenolic compounds
[10]. Due to this double set of benefits, VOO favors a better lipid
profile, reduces blood pressure (BP) levels, endothelial dysfunction,
and the inflammatory and prothrombotic environment [11].
Tree nuts that have a unique fatty acid (FA) profile character-
ized by a high (MUFA+PUFA)/SFA ratio are also typical of the
MD pattern. Although only some epidemiological studies have
reported the possible benefits of nut consumption for type 2
diabetes and some cancers, their results have been remarkably
consistent regarding CVD [12]. Apart from their favorable lipid
profile, nuts contain vegetable proteins, L-arginine, fiber, folic
acid, magnesium, copper, and different types of antioxidants such
as flavonoids, polyphenols and tocopherols, which contribute to
the cardioprotective properties of nuts via several mechanisms
[13].
Compliance with a diet is often assessed using dietary surveys,
which are associated with substantial measurement errors, whereas
biomarkers of intake are potentially independent of these errors
[14]. Therefore, an objective and accurate way to monitor fat
quality is to record the plasma FA composition [14]. Individual
plasma FA are generally expressed as a percentage of total FA.
Therefore, changes in one FA may affect the levels of several other
FA. Hence, considering the overall pattern of plasma FA may be a
more useful measure of dietary quality than individual FA.
There is increasing evidence that the plasma FA composition
may be influenced by diet [15–18] which may be useful for
primary prevention, since an altered FA composition has been
associated in several cross-sectional and observational studies with
insulin resistance and diabetes [18,19], obesity [20], CVD [21],
and MetS [22]. However, studies assessing the effect that changes
in the diet have on the FA profile and their relation with MetS
remain scarce. Therefore, within the framework of a randomized
controlled trial designed to compare the effects of two MD, one
supplemented with VOO and another supplemented with nuts,
with those of a low-fat diet on the cardiovascular outcomes among
subjects at high risk of CVD (PREDIMED Study) [23,24], the aim
of this substudy was to analyze the effect of these diets on the
plasma FA profile and its relation with MetS status after 1 year of
intervention in participants recruited in the Barcelona north,
Reus, and Pamplona centers.
Methods
Study design
The PREDIMED (PREvencio´n con DIeta MEDiterra´nea)
study is a large, parallel-group, multicenter, randomized, con-
trolled, 5-year clinical trial aimed at assessing the effects of the
Mediterranean diet on the primary prevention of cardiovascular
disease. The main outcome is an aggregate of cardiovascular
events (cardiovascular death, nonfatal myocardial infarction, or
nonfatal stroke). The trial was registered with Current Controlled
Trials, London (Identifier: ISRCTN35739639). The detailed
protocol of the study has been published elsewhere [23,24]. The
protocol for this trial and supporting CONSORT checklist are
available as supporting information; see Checklist S1 and Protocol
S1, S2 and S3. The trial is currently ongoing with 7447
participants at high risk of CVD assigned randomly to three
intervention groups: Mediterranean diet supplemented with virgin
olive oil (MD+VOO), Mediterranean diet supplemented with
mixed nuts (MD+nuts), or low-fat diet (Control). The present
substudy was designed to assess the effects of the dietary
interventions on the plasma FA profile and MetS status, two of
the secondary outcomes of the PREDIMED study. We report, the
results after 1 year’s intervention in a subset of participants
recruited in three centers of the PREDIMED trial (Barcelona
North, Reus, and Pamplona).
Ethics statement
The Institutional Review Board of the ten participating
recruitment centers of the PREDIMED trial approved the study
protocol and the participants signed an informed consent. In
particular, the current substudy was approved by the Comite´ Etic
d’Investigacio´ Clı´nica de l’Hospital de Sant Joan, Reus (Tarra-
gona), the Comisio´n de Etica de la Facultad de Medicina de la
Universidad de Navarra, Pamplona (Navarra) and the Comite´
d’Etica e Investigacio´ de l’Institut Municipal d’Investigacio´
Me`dica (IMIM), Barcelona (Barcelona).
Participants
Eligible participants for the PREDIMED Study were commu-
nity-dwelling men, aged 55 to 80 years, and women, aged 60 to 80
years, who met at least one of the two following criteria: diagnosis
of type 2 diabetes or presence of three or more CVD risk factors
(smoking, hypertension, dyslipidemia, overweight or obesity, and
family history of premature coronary heart disease (CHD)) [24].
For the present study, 2054 participants were recruited between
June 2003 and May 2006 in the Barcelona (n = 320), Reus
(n = 678) and Navarra (n = 1056) centers, three of the ten
recruitment nodes of the PREDIMED trial. After a screening
visit, participants were randomly assigned to one of three diet
groups by means of a computer-generated random-number
sequence. The plasma FA composition was measured in 22% of
the participants who entered this substudy at baseline (n = 450).
These participants were selected at random, and matched by age
and sex. However, as some participants were lost during follow-up
(Figure 1), the final number of participants studied was 424.
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Interventions
Participants randomized to each of the three interventions had a
face-to-face interview with the dietitian plus a group session. The
same dietitian delivered the interventions to the three groups in
each center. In the individual session, and based on the
individuals’ adherence to the MD or to the low-fat diet according
to a 14-point score and 9-point score questionnaire, respectively,
each participant received personal recommendations for changes
to be introduced to their diet in order to achieve the goals of the
assigned intervention group during a 30-min session. Positive
recommendations for increasing the consumption of vegetables,
fruits, legumes, fish and seafood, and white meats, were given to
each group. Negative recommendations included limiting the
consumption of red and processed meats, fat-rich dairy products,
sweets and pastries, snacks and sweetened beverages. However,
recommendations for total fat intake differed between the two MD
groups and the low-fat diet groups. Therefore, whereas partici-
pants in the low-fat group were advised to reduce all types of fat,
recommendations for the MD groups included increasing the
intake of vegetable fats and oil. No energy restrictions were
suggested for any of the intervention groups. Group sessions (up to
20 participants) were organized separately for each of the three
intervention groups. The dietitian provided informative talks and
written material, with descriptions of target foods, seasonal
shopping lists, meal plans, and recipes. Participants in the MD
groups were given a free 3-month supply of VOO (1 L/wk) or
mixed nuts (30 g/d, as 15 g walnuts, 7.5 g hazelnuts and 7.5 g
almonds). The individual and group visits were repeated every 3
months with the same content, with the exception that shopping
lists and recipes varied with the season of the year. All participants
had free and continuous access to their center’s dietitian
throughout the study.
Measurements
At baseline participants were administered several question-
naires [23,24]: (a) a 14-item questionnaire assessing the degree of
adherence to the MD (values of 0 to 1 were assigned to each item,
so that a score of 14 points meant the maximum adherence); this
was an extension of a previously validated questionnaire; (b) a
general 47-item questionnaire about education, lifestyle, medical
conditions, and medication use; (c) a 137-item food frequency
questionnaire (FFQ) adapted from a previously validated FFQ;
and (d) a validated Spanish version of the Minnesota Leisure-Time
Physical Activity Questionnaire. Moreover, participants under-
went anthropometric and BP measurements and collection of
fasting blood samples. All examinations were repeated at 1 year,
with the exception of the general questionnaire, which was
substituted by a follow-up questionnaire.
Anthropometry
The anthropometric measures used in this study were height
(m), weight (kg), body mass index (BMI, calculated as weight in
kg/height2 in m2) and waist circumference (WC). Height and
weight (with light clothing and no shoes) were recorded using a
Figure 1. Trial flow-chart. Flow of patients through the present study involving three recruitment centres of the PREDIMED trial (Barcelona North,
Reus, and Pamplona). FA indicates fatty acid; MD, Mediterranean diet; VOO, virgin olive oil.
doi:10.1371/journal.pone.0085202.g001
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calibrated balance beam scale and a wall-mounted calibrated
stadiometer, respectively. Waist circumference was measured
using an anthropometric measuring tape, at a horizontal plane
midway between the lowest rib and the iliac crest. Blood pressure
was measured in triplicate with a validated semi-automatic
sphygmomanometer after a minimum of 5 min rest in the seated
position.
Laboratory measurements
Blood samples were collected after an overnight fast, coded,
shipped to a central laboratory, and stored at 280uC until
analyses. Laboratory technicians were blinded to the intervention.
Plasma glucose level was analyzed using the glucose-oxidase
method; total serum cholesterol (TC) and triglyceride (TG) levels
were measured using enzymatic procedures; and high-density
lipoprotein cholesterol (HDL-C) level was determined after
precipitation with phosphotungstic acid and magnesium chloride
[24]. The plasma FA profile was determined by fast gas
chromatography with a previous derivatization to their corre-
sponding fatty acid methyl esters [25]. Results were expressed as
relative percentages of total FA. The average of two measures was
used for the analysis of laboratory variables both at baseline and 1
year.
Metabolic syndrome definition
The recent definition of MetS proposed by six major
organizations and societies (IDF, NHLBI, AHA, WHF, IAC,
and IASO) [1] was used in the present study, such that the
presence of any three of the five following risk factors constitutes a
diagnosis of MetS: elevated WC, elevated TG ($150 mg/dL),
reduced HDL-C (,40 mg/dL in men and ,50 mg/dL in
women), elevated BP (SBP $130 mmHg and/or DBP
$85 mmHg), and elevated fasting glucose ($100 mg/dL). Drug
treatment for these specific conditions is an alternative indicator.
In this definition, it is possible to use either the IDF or the AHA/
NHLBI cut-off limits for WC ($94 cm for men and $80 cm for
women, or .102 cm for men and .88 cm for women,
respectively) in European populations. The latter was used in the
present study.
Statistical analysis
All values are presented as mean 6 SD, unless otherwise
indicated. Kolmogorov-Smirnov tests were carried out to check
variable distribution. Since the statistical distribution of plasma FA
concentrations was found to be skewed, geometric means were
used to describe FA concentrations. Moreover, FA concentrations
were log-transformed for analysis to improve normality. Analysis
of variance (ANOVA) and the x2 test were used to determine
differences in baseline characteristics in individuals with and
without MetS for continuous and categorical variables, respec-
tively. Besides the assignation to one MD group, participants were
divided into four MetS groups: those who did not change their
MetS status after the 1-year intervention (always/never) and those
whose status changed (reversion/incidence). Within- and between-
group changes in plasma FA concentrations were examined with
paired t tests and ANOVA followed by the Duncan test,
respectively. The relationship between these changes and 1-year
changes in metabolic risk factors was determined by partial
correlation analysis controlling for gender, age, smoking status,
occupation, educational level, baseline energy intake, 1-year
changes in energy intake, and medication for hypercholesterol-
emia, BP, and diabetes. To examine the associations between
these changes and the incidence and reversion of MetS,
participants were categorized by quartiles of 1-year changes in
plasma concentrations of FA. Then, a logistic regression analysis
was carried out to calculate the odds ratios (OR) and 95%
confidence intervals (CI) of the incidence and reversion of MetS
according to these quartiles. Finally, we used McNemar’s test and
logistic regression models to assess within- and between-quartile
changes in the prevalence of MetS. All logistic regression models
were adjusted for potential confounding factors (age, gender,
baseline MetS status, baseline overweight/obesity, and 1-year
changes in BMI), and the lowest quartile was used as the reference.
For all analyses, two-sided significance was determined at p,0.05.
Analyses were performed using SPSS version 15.0 (SPSS Inc.,
Chicago, IL, USA).
Results
The baseline characteristics of the 424 participants (175 men
and 249 women) that completed the intervention program at 1
year are detailed in Table 1 according to their MetS status. By
design, participants were mostly overweight subjects with an
elevated number of CVD risk factors. Of the total population,
92.7%, 84.2%, 68.4%, and 45.8% were overweight or obese,
hypertensive, dyslipidemic, or had type II diabetes, respectively.
The prevalence of MetS in the study population was 67.7%,
whereas that of its components was 96.0%, 64.6%, 63.8%, 58.5%,
and 55.7%, for elevated BP, WC, fasting glucose, TG, and
reduced HDL-C, respectively. As expected, most of the charac-
teristics associated with MetS were significantly higher among
those who presented with this condition.
Table 2 shows the baseline plasma FA profile and 1-year
changes according to the intervention group. Participants in the
MD+VOO group showed significantly increased plasma concen-
trations of palmitic acid (PA, C16:0) and oleic acid (OA, C18:1n-9)
but significantly reduced proportions of margaric acid (MGA,
C17:0), stearic acid (SA, C18:0), and linoleic acid (LA, C18:2n-6).
In contrast, subjects in the MD+nuts group showed a significant
increase in the levels of PA, LA, and a-linolenic acid (ALA,
C18:3n-3), but significantly reduced proportions of myristic acid
(MA, C14:0), MGA, palmitoleic acid (POA, C16:1n-7), and
dihommo-c-linoleic acid (DGLA, C20:3n-6). Finally, those in the
control group only showed a significant increase in the plasma
levels of PA with a reduction in MGA and ALA after 1 year of
intervention. Between-group differences were only significant for
some MUFA (OA) and PUFA (LA, DGLA, and ALA).
The baseline plasma FA profile and 1-year changes according to
the 1-year change in MetS status are shown in Table 3.
Participants who never had MetS showed significantly higher
proportions of PA, OA, and ALA, but reduced proportions of
DGLA after 1 year of intervention. In turn, participants in the
MetS reversion group showed significantly increased plasma levels
of OA and ALA, whereas those in the MetS incidence group
showed significantly increased plasma concentrations of MA and
PA, but presented a reduction in the levels of MGA and ALA.
Finally, participants that always had MetS during the intervention
showed a significant increase in the proportions of PA and OA
with a significant reduction in the plasma concentrations of MGA
and SA. Between-group changes in FA concentrations were
significantly different only in the case of OA.
After 1 year of intervention, changes in several specific FA were
related to changes in various metabolic risk factors (Table 4).
When significant, changes in most SFA and POA were adversely
associated with changes in metabolic risk factors, whereas changes
in most PUFA were associated in a beneficial way. In addition, we
also calculated partial correlation coefficients to look for possible
relationships between food groups and plasma FA composition.
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Since plasma concentrations of OA, LA, and ALA are good
biomarkers of olive oil, seed oil, and walnut consumption, the 1-
year changes reported indicate good adherence to the food
supplied. The increase in plasma levels of OA and ALA in the
MD+VOO and MD+nuts groups indicates good adherence to
OO and nuts, respectively, whereas the decrease in the
concentration of LA and the clear inverse relation found between
OO consumption and n-6 PUFA levels suggests that people in the
MD+VOO group replaced seed oils with VOO.
In logistic regression analyses, higher changes in the proportions
of MA and PA were related to an increased incidence of MetS (p
between quartiles quartiles = 0.037 and 0.046, respectively), with
an OR (95% CI) for the 1st, 2nd, 3rd, and 4th quartiles of changes of
1.00, 1.90 (0.44, 8.11), 2.70 (0.65, 11.24), and 6.43 (1.53, 27.03),
and 1.00, 2.17 (0.46, 10.3), 4.06 (0.96, 21.20), and 8.65 (1.79,
41.78), respectively. One the other hand, both biomarkers of the
foods supplied, OA and ALA, were found to be protective against
MetS. Hence, changes in OA and ALA concentrations were
inversely associated with the incidence of MetS (p between
quartiles = 0.035 and 0.032, respectively) and showed a stronger
direct relation with MetS reversion (p between quartiles = 0.005
and 0.020, respectively) (Figure 2). No other significant associa-
tions were found between changes in the levels of the remaining
FA and the incidence or reversion of MetS. Finally, changes in the
Table 1. Baseline characteristics of participants completing 1-year intervention.A
Characteristics No MetS (n= 137) MetS (n= 287) pB
Age (years) 67.566.1 67.765.8 0.833
Men (%) 52.6 35.9 0.001
Weight (kg) 71.569.8 75.5610.4 ,0.001
BMI (kg/m2) 27.963.0 30.063.1 ,0.001
Overweight or obese (%)C 86.1 95.8 ,0.001
Hypertension (%)D 84.7 84.0 0.854
Dyslipidemia (%)E 56.9 73.9 ,0.001
Type 2 diabetes mellitus (%) 33.6 51.6 0.001
Family history of premature CHD (%)F 21.9 19.5 0.805
Current smoker (%) 18.2 12.5 0.118
MetS components (%)G
Elevated WC 29.9 81.2 ,0.001
Elevated TG 21.2 76.3 ,0.001
Reduced HDL-C 19.7 72.8 ,0.001
Elevated BP 90.5 98.6 ,0.001
Elevated fasting glucose 36.5 76.9 ,0.001
Medications (%)
Aspirin or antiplatelet drugs 21.2 24.4 0.593
Antihypertensive agents 67.9 75.3 0.110
Hipolypidemic agents 19.0 56.4 ,0.001
Insulin 6.6 6.3 0.783
Hypoglycemic agents 16.8 34.8 ,0.001
Occupation (%)
Worker 16.1 10.2 0.078
Unemployed or unfit 24.1 31.2 0.141
Retired 59.9 58.6 0.745
Education level (%)
None 2.2 4.6 0.237
Primary school 64.4 72.3 0.116
Secondary school 25.9 15.6 0.012
University 7.4 7.4 0.995
MetS, Metabolic Syndrome; BMI, body mass index; CHD, coronary heart disease; WC, waist circumference; TG, triglycerides; HDL-C, high density lipoprotein cholesterol;
BP, blood pressure.
AValues are expressed as mean 6 SD or percentage of participants.
Bp value for comparison between groups calculated by one-factor ANOVA for continuous variables or x2 test for categorical variables.
CBMI$25 kg/m2.
DSystolic BP$140 mmHg or diastolic BP$90 mmHg or antihypertensive medication.
ELDL cholesterol $160 mg/dL or lipid-lowering therapy; HDL cholesterol #40 mg/dL in men or #50 mg/dL in women.
FDefinite myocardial infarction or sudden death before 55 years in male first-degree relatives or before 65 years in female first-degree relatives.
GThe metabolic syndrome components are defined according to the IDF, NHLBI, AHA, WHF, IAC, and IASO recent criteria.
doi:10.1371/journal.pone.0085202.t001
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Table 2. Plasma fatty acid levels at baseline and 1-year changes according to the intervention groups.A
Fatty acid MD+VOO (n= 142) pB MD+Nuts (n= 141) pB Control (n= 141) pB pC
SFA
MA (C14:0)
Baseline 0.5760.27 0.6360.31 0.6260.27
Change 0.012a60.28 0.573 20.060b60.33 0.008 20.0087a,b60.33 0.714 0.067
PA (C16:0)
Baseline 21.5562.20 21.3762.06 21.9662.45
Change 0.5162.00 0.002 0.3761.98 0.024 0.6762.57 0.001 0.517
MGA (C17:0)
Baseline 0.2760.34 0.3060.35 0.2860.33
Change 20.03060.34 0.034 20.03760.42 0.048 20.03160.38 0.036 0.981
SA (C18:0)
Baseline 6.7661.16 6.9061.09 6.7461.26
Change 20.2561.23 0.005 20.1561.20 0.101 20.05561.46 0.604 0.325
MUFA
POA (C16:1n-7)
Baseline 1.3560.69 1.3360.57 1.3660.59
Change 20.01260.49 0.766 20.09360.55 0.033 20.03460.58 0.410 0.221
OA (C18:1n-9)
Baseline 25.2964.45 26.4263.98 26.7564.48




Baseline 29.4765.42 28.0964.72 28.0064.98
Change 21.94a64.26 ,0.001 1.81b63.92 ,0.001 0.82b65.89 0.086 ,0.001
GLA (C18:3n-6)
Baseline 0.3960.18 0.4060.20 0.4160.18
Change 0.01360.20 0.536 20.002760.15 0.841 0.01960.20 0.264 0.667
DGLA (C20:3n-6)
Baseline 1.5060.35 1.5060.36 1.4860.34
Change 20.040a,b60.32 0.132 20.077a60.24 ,0.001 0.030b60.37 0.294 0.010
AA (C20:4n-6)
Baseline 6.7561.74 6.7261.63 6.6461.75
Change 20.2261.23 0.057 20.08061.21 0.408 0.08161.59 0.536 0.160
Series n-3 FA
ALA (C18:3n-3)
Baseline 0.3360.16 0.3260.12 0.3360.15
Change 20.021a60.18 0.101 0.15b60.19 ,0.001 20.032a60.19 0.020 0.028
EPA (C20:5n-3)
Baseline 0.7460.82 0.7360.54 0.7160.65
Change 0.055a60.78 0.196 0.084a60.60 0.062 20.065b60.67 0.067 0.060
DHA (C22:6n-3)
Baseline 2.5160.95 2.4860.81 2.4360.69
Change 0.012a,b61.25 0.899 20.081a60.83 0.215 0.18b61.07 0.068 0.073
MetS, Metabolic Syndrome; MA, myristic acid; PA, palmitic acid; MGA, margaric acid; SA, stearic acid; POA, palmitoleic acid; OA, oleic acid; LA, linoleic acid; GLA, c-
linolenic acid; DGLA, dihommo-c-linoleic acid; AA, arachidonic acid; ALA, a-linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid.
Values in the same row (Change) with different superscript letters (a,b) are significantly different (p,0.05 by Duncan test).
AValues are expressed as geometric mean (% of total fatty acids) 6 SD.
Bp for within-group differences from baseline by paired t test.
Cp for between-group differences from baseline by one-factor ANOVA.
doi:10.1371/journal.pone.0085202.t002
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Table 3. Plasma fatty acid levels at baseline and 1-year changes according to the 1-year change in the MetS status.A
Fatty acid Never (n= 97) p
B Reversion (n= 44) pB Incidence (n= 40) pB Always (n= 243) pB pC
SFA
MA (C14:0)
Baseline 0.5360.21 0.5860.31 0.5660.26 0.6560.30
Change 20.012a60.22 0.552 20.048a60.34 0.212 0.089b60.30 0.024 20.034a60.34 0.085 0.057
PA (C16:0)
Baseline 20.7061.86 21.7762.66 21.4962.24 22.0062.22
Change 0.58a,b62.06 0.003 0.16a62.65 0.666 0.98b61.81 0.001 0.47a,b62.22 0.001 0.314
MGA (C17:0)
Baseline 0.2760.28 0.2660.31 0.3060.34 0.2960.36
Change 20.02160.26 0.224 20.03960.32 0.088 20.07260.36 0.007 20.02960.44 0.028 0.428
SA (C18:0)
Baseline 6.8361.24 6.8360.96 6.7360.79 6.7961.23
Change 20.07361.40 0.535 20.2561.01 0.087 20.1960.80 0.136 20.1661.37 0.036 0.837
MUFA
POA (C16:1n-7)
Baseline 1.1860.69 1.3560.60 1.3160.58 1.4360.59
Change 20.06760.51 0.147 20.06760.51 0.317 20.0002960.45 0.997 20.03460.57 0.296 0.783
OA (C18:1n-9)
Baseline 24.9664.02 25.1664.82 26.3164.20 26.7964.29




Baseline 29.7964.65 28.4765.42 29.8663.69 27.8265.30
Change 0.7864.46 0.088 1.1466.30 0.215 20.3163.51 0.582 20.06465.19 0.844 0.290
GLA (C18:3n-6)
Baseline 0.3960.18 0.4160.14 0.4060.22 0.4060.19
Change 20.01860.16 0.306 0.007860.19 0.726 0.01460.20 0.643 0.02160.19 0.145 0.437
DGLA (C20:3n-6)
Baseline 1.4860.34 1.4860.36 1.5360.36 1.4960.35
Change 20.07660.30 0.010 0.04860.42 0.410 20.04460.30 0.306 20.02260.30 0.253 0.134
AA (C20:4n-6)
Baseline 6.9861.64 6.5261.59 6.7461.71 6.6261.75
Change 20.24a61.27 0.056 0.38b61.21 0.050 20.35a61.31 0.063 20.044a,b61.41 0.622 0.036
Series n-3 FA
ALA (C18:3n-3)
Baseline 0.3260.14 0.2960.15 0.3560.14 0.3360.15
Change 0.041a60.20 0.010 0.087a60.23 0.008 20.061b60.19 0.025 0.021a60.21 0.052 0.009
EPA (C20:5n-3)
Baseline 0.8460.66 0.7560.80 0.6360.34 0.7060.71
Change 0.03660.73 0.484 0.02760.96 0.757 0.00260.41 0.969 0.01860.66 0.506 0.988
DHA (C22:6 n-3)
Baseline 2.6160.81 2.5860.93 2.3560.59 2.4260.64
Change 0.01961.06 0.844 0.05461.08 0.717 0.1160.97 0.400 0.02461.09 0.703 0.953
MetS, Metabolic Syndrome; MA, myristic acid; PA, palmitic acid; MGA, margaric acid; SA, stearic acid; POA, palmitoleic acid; OA, oleic acid; LA, linoleic acid; GLA, c-
linolenic acid; DGLA, dihommo-c-linoleic acid; AA, arachidonic acid; ALA, a-linolenic acid; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid.
Values in the same row (Change) with different superscript letters (a,b) are significantly different (p,0.05 by Duncan test).
AValues are expressed as geometric mean (% of total fatty acids) 6 SD.
Bp for within-group differences from baseline by paired t test.
Cp for between-group differences from baseline by one-factor ANOVA.
doi:10.1371/journal.pone.0085202.t003
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prevalence of MetS according to the quartiles of change in OA
and ALA were 10.4%, 5.7%, 25.7%, and 212.3% (p between
quartiles = 0.002), and 10.4%, 4.7%, 29.4%, and 29.4% (p
between quartiles = 0.002), respectively. Moreover, no significant
weight changes were observed across the quartiles of changes in
OA and ALA (p between quartiles = 0.931 and 0.745, respective-
ly).
Discussion
To our knowledge, the present study is the first randomized
controlled trial to have assessed the effect of a Mediterranean
dietary pattern on the overall plasma FA profile of individuals at
high risk of CVD and its relation with MetS. Our results show a
robust association between two MD and changes in the FA
composition after 1 year of intervention.
Participants in the MD+VOO group showed reduced plasma
levels of MGA, SA, and LA but increased levels of PA and OA. The
findings in the MD+VOO group (40% and 20.5% of energy from
fats and MUFA, respectively) are consistent with those of other
intervention studies using MUFA-enriched diets high in fat content
and with a similar nutrient composition [26,27]. This is important
since total fat intake modifies the plasma FA composition [28]. In
both studies, people receiving a MUFA diet (40%/20% and 39%/
20.3% of energy from fats/MUFA, respectively) showed increased
levels of PA and decreased levels of SA, although these changes were
only significant in the former study; POA levels did not change
significantly. In addition, the LA concentrations were significantly
reduced with an increase in OA due to supplementation. In turn,
the MD+nuts group showed reduced concentrations of MA, MGA,
POA, and DGLA, while increasing the levels of LA and ALA. These
results are consistent with a recent controlled dietary intervention
that reported significantly lower serum proportions of PA, SA,
POA, and DGLA, but significantly higher proportions of LA and
ALA in slightly overweight and hyperlipidemic healthy subjects that
consumed a rapeseed oil-based diet rich in MUFA and PUFA
(particularly OA, LA, and ALA) compared to a diet high in
saturated fat [15]. Interestingly, the MD+nuts group diet induced a
FA composition that was beneficial in the face of cardiometabolic
disease, since high proportions of PA, POA, and DGLA, and
reduced levels of LA have been related to several cardiometabolic
diseases [18–21], including MetS [22]. Consistently, we also found
Table 4. Partial correlation coefficients between 1-year changes in plasma fatty acids and 1-year changes in metabolic risk factors
(n= 424) and between food groups and plasma fatty acids.A
Fatty acid WC BMI TC HDL-CB LDL-C TGB SBP DBP glucose Food groups
SFA
MA (C14:0) 0.02 0.00 0.13* 0.01 0.10* 0.10* 0.06 0.03 0.06 cheese (0.10*)
PA (C16:0) 0.00 0.01 0.09 20.01 0.02 0.17* 0.06 20.01 0.07
MGA (C17:0) 20.06 20.01 0.04 20.12* 0.10 20.04 20.07 20.09 20.03 milk (0.11*)
SA (C18:0) 0.06 20.02 20.02 0.01 0.03 20.13* 20.06 20.03 0.00
MUFA
POA (C16:1n-7) 0.03 0.14** 0.06 20.02 0.00 0.21*** 0.00 0.02 0.06




LA (c18:2n-6) 20.03 20.06 0.04 0.02 0.07 20.20** 20.02 0.02 0.01 OO (20.19***) seed
oils (0.19***), total
nuts (0.11*)
GLA (C18:3n-6) 20.01 20.02 0.05 20.08 0.05 0.08 20.04 0.03 0.01
DGLA (C20:3n-6) 20.08 0.05 0.01 0.03 0.04 20.08 0.01 0.03 20.14**
AA (C20:4n-6) 20.05 20.04 20.19** 0.02 20.08 20.32*** 20.08 20.11* 20.18***
Series n-3
ALA (C18:3n-3) 20.12* 20.09 0.05 0.07 0.07 20.05 20.06 0.04 20.07 total nuts (0.10*),
walnuts (0.17***)
EPA (C20:5n-3) 20.07 20.04 0.11* 0.10* 0.13* 20.09 0.09 0.03 0.02 white fish (0.17***),
blue fish (0.29***)
DHA (C22:6n-3) 0.02 20.09 20.05 20.04 0.01 20.13* 20.05 20.01 20.02 white fish (0.15***),
blue fish (0.25***)
WC, waist circumference; BMI, body mass index; TC, total cholesterol; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol, TG;
triglycerides; SBP, systolic blood pressure; DBP, diastolic blood pressure; MA, myristic acid; PA, palmitic acid; MGA, margaric acid; SA, stearic acid; POA, palmitoleic acid;
OA, oleic acid; LA, linoleic acid; GLA, c-linolenic acid; DGLA, dihommo-c-linoleic acid; AA, arachidonic acid; ALA, a-linolenic acid; EPA, eicosapentaenoic acid; DHA,




AAdjusted for sex, age, smoking status, occupation, educational level, baseline energy intake, 1-year changes in energy intake, and medication for hypercholesterolemia,
blood pressure, and diabetes.
BLog-transformed for normality.
doi:10.1371/journal.pone.0085202.t004
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that increases in individual SFA and POA correlated adversely with
several metabolic risk factors.
We also examined the association between the adherence to a
MD and the incidence, reversion, and changes in prevalence of
MetS. Rather than performing analyses according to the
intervention group, we used biomarkers of the foods supplied to
each group for two reasons. First, as inhabitants of a Mediterra-
nean region, the participants in the control group consumed a
lower amount of fatty foods characteristic of the Western diet but
not a lower amount of VOO or nuts, which could have attenuated
any differences between groups. Secondly, since biomarkers are
potentially independent of the errors associated with self-report
Figure 2. Odds ratios (95% confidence intervals) of 1-year MetS incidence and reversion, and MetS prevalence. Odds ratios at baseline
and 1 year by quartiles of 1-year changes in plasma levels of oleic and a-linolenic acids are shown in the left and right panels, respectively. The lowest
quartile was chosen as the reference for the odds ratio calculations. Different superscript letters indicate significantly different 1-year prevalence
changes between quartiles (p,0.05 by logistic regression model), while an * indicates a significant 1-year prevalence change within each quartile
(p,0.05 by McNemar’s test).
doi:10.1371/journal.pone.0085202.g002
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methods [14], they provide an objective and accurate measure of
the consumption of MD foods among participants independently
of the assigned group. Some FA are considered to be indirect
biomarkers of the consumption of individual foods or food groups.
This is the case when the food source is the primary source of the
FA and it is stable in the sampling medium [14]. According to the
correlation analysis, plasma concentrations of OA and ALA were
good biomarkers of OO and walnut intake, respectively. Walnuts
are characterized by their high ALA content, which, in turn,
cannot be synthesized endogenously. Therefore the correlation
between ALA in plasma and walnut intake was expected.
Regarding OA, being a MUFA, it can be synthesized endoge-
nously from either carbohydrates (CHO) or SFA, particularly
when MUFA intakes are lower. Moreover, although OO is the
richest dietary source of OA, it is also a major component of most
animal fats and makes up a sizable fraction of most vegetable oils.
However, while animal fats rich in OA typically contribute
considerably to its intake in other European countries, OO was the
largest contributor of total fat (70%) in our Catalan population.
Moreover, 70–80% of its MUFA content is due to OA. Therefore,
OA was a good biomarker of OO consumption in our sample
population. In fact, the plasma levels of OA have previously been
related to their dietary source in Mediterranean populations [29].
Furthermore, tissue stores of OA were a marker of OO
consumption in Spain, but not in the other four European centers
of the EURAMIC study [30].
Using the biomarkers of foods supplied to the intervention groups
we found that the incidence and reversion rates of MetS progressed
inversely and in parallel, respectively, to increases in OA and ALA,
which resulted in significant differences in the changes in prevalence
of MetS across the quartiles of changes in both OA and ALA.
Therefore, the beneficial effect of OO and nut consumption on the
prevalence of MetS appears to be a consequence of the combination
of incidence and reversion rates. However the reduction in the
prevalence of MetS obtained in our study was much lower than that
reported by other studies showing a beneficial effect of adherence to
the MD in terms of MetS prevalence [9]. This could be due to
several factors. Firstly, participants in the other intervention studies
were younger and all had MetS or impaired glucose tolerance at
baseline. Secondly, the CHO intake in those studies was higher than
that of our study population (.55% of energy vs. 40%) and
extensive research has achieved consensus that reducing dietary
CHO is a critical approach to treating or managing the
manifestations of MetS [31]. Finally, energy intake was reduced
and physical activity increased in the previous studies so as to
achieve weight loss, which is considered the number one priority
when treating MetS [6]. However, no restrictions were prescribed in
any of our groups, which resulted in a non-significant weight change
across the quartiles of changes in OA and ALA. Indeed, a recent
study reported that a MD without weight loss led to non-significant
changes in the components or prevalence of MetS compared to the
control diet, whereas only a small reduction in body weight (10%)
reduced the prevalence of MetS by more than 50% [32]. However,
the magnitude of the weight loss did not predict the degree of
improvement in MetS components while on the MD and patients
with the most deteriorated baseline MetS profile presented
important cardiometabolic benefits even on a MD without weight
loss, suggesting that the MD may achieve beneficial effects even in
the absence of weight loss, as was our case.
Apart from the biomarkers of the food supplied, we found that
MA and PA were adversely associated with the incidence of MetS.
This supports the findings of previous studies about dietary fat
quality and disease risk. Hence, substituting unsaturated fat or
CHO for SFA impairs insulin sensitivity [33] and induces a FA
pattern similar to that observed in people with MetS [17], which is
also caused by a diet rich in SFA [15]. Interestingly, we found that
when participants were classified according to their change in
MetS status, the changes in these two SFA and the two biomarkers
of foods supplied evolved in the MetS incidence group in the
opposite direction to that of the other groups, with the exception of
PA. Thus, while the incidence group showed a significant increase
in the proportions of MA and PA and a reduction in the levels of
OA and ALA, subjects in the other groups presented a non-
significant decrease in the proportions of MA but an increase in
the OA and ALA levels. Importantly, although between-group
changes in these four FA were not always significant, they differed
significantly between the MetS incidence and reversion groups. In
fact participants in the reversion group showed the highest
reduction in MA, the lowest increase in PA, and the highest
increase in both OA and ALA among the non-incident groups,
which could explain the change in their MetS status. However, the
increase in OA and ALA concentrations observed in participants
who always had MetS was probably not enough compared with
that of the MetS reversion group to experience a change in their
MetS status after the intervention. Furthermore, participants who
never had MetS during the intervention probably did not present
MetS after 1 year of intervention because they had also
significantly increased both OA and ALA.
Interestingly, all these effects were observed without a weight
increase despite the high fat content of both MDs. In fact, a meta-
analysis of 21 epidemiological studies regarding MD and obesity
showed that no studies reported significantly increased obesity in
response to a MD. Moreover, over half of the studies provided
evidence that adherence to a MD was associated with less
overweight/obesity or promoted weight loss [34]. This lack of
weight gain and the improvement in overweight or obesity may be
due to the increased postprandial fat oxidation, diet-induced
thermogenesis and overall daily energy expenditure induced by
OO [35] and nut [36] consumption, as well as to a satiating effect
[36,37].
Since the primary endpoint for the treatment of MetS is to reduce
the risk of CVD, traditional dietary recommendations such as those
proposed by the NCEP, AHA and NHLBI essentially involve
following a low-fat diet and achieving weigh reduction by a
combination of reduced caloric intake and increased physical
activity. In our study, however, we found that a high-fat (.40% of
energy) non-energy-restricted diet showed a reduction in MetS
prevalence without the need for weight loss or prescribed physical
activity. There are several important aspects to consider regarding
the MD followed in this study. First of all, it is highly palatable,
decreases hunger, and promotes satiety, hence improving long-term
adherence compared to low-fat energy-restricted diets [31].
Secondly, no weight gain was observed in participants with high
VOO or nut consumption. Finally, a usual consequence of low-fat
diets is unrestricted CHO intake, which has been shown to result in
reduced HDL-C levels and raised TG levels, thus exacerbating the
MetS status [31]. Therefore, the results of this study suggest that
there is no rationale for maintaining the fear that a MD rich in fats
of vegetable origin may cause weight gain, and that it may be a
useful alternative to traditional low-fat diets for the dietary
treatment of MetS.
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